Clinical Observation of Shenxie Zhitong Capsule in Treating Diabetic Peripheral Neuropathy of Stagnant Blockade of Collaterals

Shen-yi JIN; Qing-guang CHEN; Zheng YAO; Hao LU

doi:10.13422/j.cnki.syfjx.20202430

您当前的位置：

首页 >

文章列表页 >

Clinical Observation of Shenxie Zhitong Capsule in Treating Diabetic Peripheral Neuropathy of Stagnant Blockade of Collaterals

Clinic | 更新时间：2021-03-29

- Clinical Observation of Shenxie Zhitong Capsule in Treating Diabetic Peripheral Neuropathy of Stagnant Blockade of Collaterals
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 8, Pages: 81-87(2021)
- 作者机构：
  
  上海中医药大学附属曙光医院，上海 200120
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20202430
  CLC： R22;R242;R2-031;R287
- Received：22 September 2020，
  
  Published Online：13 October 2020，
  
  Published：20 April 2021
- 稿件说明：
移动端阅览
金燊懿,陈清光,姚政等.参蝎止痛胶囊治疗糖尿病周围神经病变脉络瘀阻证临床观察[J].中国实验方剂学杂志,2021,27(08):81-87.

JIN Shen-yi,CHEN Qing-guang,YAO Zheng,et al.Clinical Observation of Shenxie Zhitong Capsule in Treating Diabetic Peripheral Neuropathy of Stagnant Blockade of Collaterals[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(08):81-87.
金燊懿,陈清光,姚政等.参蝎止痛胶囊治疗糖尿病周围神经病变脉络瘀阻证临床观察[J].中国实验方剂学杂志,2021,27(08):81-87. DOI： 10.13422/j.cnki.syfjx.20202430.

JIN Shen-yi,CHEN Qing-guang,YAO Zheng,et al.Clinical Observation of Shenxie Zhitong Capsule in Treating Diabetic Peripheral Neuropathy of Stagnant Blockade of Collaterals[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(08):81-87. DOI： 10.13422/j.cnki.syfjx.20202430.

摘要

目的

观察参蝎止痛胶囊治疗糖尿病周围神经病变（DPN）脉络瘀阻证的临床疗效，评价其有效性和安全性。

方法

采用随机对照试验的设计方法，在均接受基础治疗的情况下，将104例患者分为参蝎止痛胶囊治疗组（治疗组，53例）和硫辛酸片对照组（对照组，51例），观察治疗前后两组患者多伦多神经病变评分（TCSS），犹他神经症状评分（UENS），中医证候评分；视觉模拟评分（VAS），踝肱指数（ABI），震动感觉阈值（VPT）；终点事件足溃疡、行经皮冠状动脉介入术（PCI），死亡及复合终点事件；糖脂代谢相关指标及安全性指标。

结果

与本组治疗前比较，治疗后两组患者TCSS，UENS，中医证候评分均显著降低（

0.01），VAS，糖化血红蛋白（HbA1c）均明显降低（

0.05）；随访时两组患者右ABI，总胆固醇（TC），低密度脂蛋白（LDL）水平均明显降低（

0.05），高密度脂蛋白（HDL）水平均明显升高（

0.05），对照组餐后2 h血浆葡萄糖（2 h PG），HbA1c水平均明显升高（

0.05）。治疗后与对照组比较，治疗组的VAS明显降低（

0.05）。治疗后及随访时，与对照组比较，治疗组的2 h PG水平均明显降低（

0.05）。两组患者间的终点事件及安全指标，差异无统计学意义，但治疗组复合终点事件发生率趋势较对照组低。

结论

参蝎止痛胶囊治疗糖尿病周围神经病变临床疗效确切，并在疼痛症状改善上比硫辛酸更安全有效。

Abstract

Objective

To observe the clinical efficacy of Shenxie Zhitong capsule in the treatment of diabetic peripheral neuropathy（DPN） of stagnant blockade of collaterals， and evaluate its effectiveness and safety.

Method

The 104 patients were randomly divided into the Shenxie Zhitong capsule treatment group （the treatment group， 53 patients） and the alpha lipoic acid group （control group， 51 patients）， and two groups were compared by random and contrast test. The changes of the Toronto clinical scoring system （TCSS）， utah early neuropathy scores （UENS）， traditional Chinese medicine（TCM）syndrome scores， visual analysis scale （VAS）， ankle brachial index （ABI）， vibrating perception threshold （VPT） before and after treatment were compared between two groups， and the endpoint events， such as foot ulcers， percutaneous coronary intervention （PCI）， death and composite endpoint events， related indicators of glucose and lipid metabolism and safety indicators were recorded among patients.

Result

Compared with the data before treatment， the scores of TCSS， UENS， and TCM syndromes in two groups were significantly reduced （

0.01） after treatment， and VAS and glycosylated haemoglobin A1c （HbA1c） were significantly reduced （

0.05）， during follow-up visit， the levels of right ABI，total cholesterol （TC）， and low-density lipoprotein （LDL） in two groups were significantly reduced （

0.05）， and high-density lipoprotein （HDL） level was significantly increased （

0.05）. control group in control group， the 2-hour postprandial plasma glucose （2 h PG） and HbA1c levels were significantly increased （

0.05）. Compared with control group， the VAS of the treatment group after treatment was significantly reduced （

0.05）. After treatment and during follow-up visit， compared with control group， the 2 h PG levels of the right toe in the treatment group were significantly reduced （

0.05）. There was no statistically significant difference in endpoint events and safety indicators between two groups， but the incidence trend of composite endpoint events in the treatment group was lower than that in control group.

Conclusion

Shenxie Zhitong capsule has definite clinical curative effect in treating diabetic peripheral neuropathy， which is more safe and effective than alpha lipoic acid in improving pain symptoms.

关键词

Keywords

references

KRENTZ N A J ， GLOYN A L . Insights into pancreatic islet cell dysfunction from type 2 diabetes mellitus genetics ［J］. Nat Rev Endocrinol ， 2020 ， 16 （ 4 ）： 202 - 212 .

中华医学会糖尿病学分会 . 中国2型糖尿病防治指南（2017年版）［J］. 中华糖尿病杂志， 2018 ， 10 （ 1 ）： 4 - 67 .

ROSENBERGER D C ， BLECHSCHMIDT V ， TIMMERMAN H ， et al . Challenges of neuropathic pain： focus on diabetic neuropathy ［J］. J Neural Transm ， 2020 ， 127 （ 4 ）： 589 - 624 .

RAGHU A L B ， PARKER T ， AZIZ T Z ， et al . Invasive electrical neuromodulation for the treatment of painful diabetic neuropathy： systematic review and Meta-analysis ［J］. Neuromodulation ， 2020 ， 76 （ 3 ）： 1 - 9 .

SINGH R ， KISHORE L ， KAUR N . Diabetic peripheral neuropathy： current perspective and future directions ［J］. Pharmacol Res ， 2014 ， 80 ： 21 - 35 .

张勇 . 依帕司他对于治疗糖尿病周围神经病变的疗效观察［J］. 中国现代药物应用， 2016 ， 10 （ 9 ）： 130 - 131 .

鲁佳，董勤 . 神经生长因子与糖尿病周围神经病变的相关性及针灸干预作用的研究进展［J］. 中医学报， 2011 ， 26 （ 11 ）： 1400 - 1402 .

HAN T T ， BAI J F ， LIU W ， et al . A systematic review and meta-analysis of α -lipoic acid in the treatment of diabetic peripheral neuropathy ［J］. Eur J Endocrinol ， 2012 ， 167 （ 4 ）： 465 - 471 .

ZIEGLER D ， NOWAK H ， KEMPLER P ， et al . Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid： a Meta-analysis ［J］. Diabet Med ， 2004 ， 21 （ 2 ）： 114 - 121 .

DAN Z ， ALEXANDER A ， ALEXEY B ， et al . Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy： the SYDNEY 2 trial ［J］. Diabetes Care ， 2006 ， 29 （ 11 ）： 2365 - 2370 .

PAPANAS N ， MALTEZOS E . α -Lipoic acid， diabetic neuropathy， and Nathan's prophecy ［J］. Angiology ， 2012 ， 63 （ 2 ）： 81 - 83 .

何刚，吴素琴 . 虫类药治疗糖尿病痛性神经病变体会［J］. 河北中医， 2013 ， 35 （ 10 ）： 1487 - 1488 .

姚政，陶枫，丁学屏 . 灵异胶囊治疗糖尿病周围神经病变临床观察［J］. 上海中医药杂志， 2005 ， 39 （ 8 ）： 21 - 22 .

丁学屏，叶伟成，沈远东，等 . 灵异胶囊治疗糖尿病周围神经病变及其对体表电生理的影响［J］. 上海中医药大学学报， 2001 ， 15 （ 1 ）： 27 - 29 .

ALBERTI K G ， ZIMMET P Z . Definition， diagnosis and classification of diabetes mellitus and its complications. Part 1： diagnosis and classification of diabetes mellitus provisional report of a WHO consultation ［J］. Diabet Med ， 1998 ， 15 （ 7 ）： 539 - 553 .

方朝晖，吴以岭，赵进东 . 糖尿病周围神经病变中医临床诊疗指南（2016年版）［J］. 中医杂志， 2017 ， 58 （ 7 ）： 625 - 630 .

SINGLETON R J ， BIXBY B ， RUSSELL W J ， et al . The utah early neuropathy scale： a sensitive clinical scale for early sensory predominant neuropathy ［J］. J Peripheral Nerve Soci ， 2008 ， 13 ： 218 - 227 .

AJROUD-DRISS S ， CHRISTIANSEN M ， ALLEN J A ， et al . Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy ［J］. Mol Ther ， 2013 ， 21 （ 6 ）： 1279 - 1286 .

GRIGGS R B ， SANTOS D F ， LAIRD D E ， et al . Methylglyoxal and a spinal TRPA1-AC1-Epac cascade facilitate pain in the db/db mouse model of type 2 diabetes ［J］. Neurobiol Dis ， 2019 ， 127 （ 11 ）： 76 - 86 .

SELVARAJAH D ， KAR D ， KHUNTI K ， et al . Diabetic peripheral neuropathy： advances in diagnosis and strategies for screening and early intervention ［J］. Lancet Diabetes Endocrinol ， 2019 ， 7 （ 12 ）： 123 - 127 .

任海迪，胡晓灵 . 糖尿病周围神经病变中西医研究进展［J］. 新疆中医药， 2018 ， 36 （ 6 ）： 79 - 82 .

陈瑛，姚政，陈清光，等 . 虫类药物治疗糖尿病周围神经病变的疗效和机制研究概况［J］. 时珍国医国药， 2018 ， 29 （ 1 ）： 182 - 184 .

FARMER K L ， LI C ， DOBROWSKY R T . Diabetic peripheral neuropathy： should a chaperone accompany our therapeutic approach？［J］. Pharmacol Rev ， 2012 ， 64 （ 4 ）： 880 - 900 .

BONHOF G J ， HERDER C ， STROM A ， et al . Emerging biomarkers， tools， and treatments for diabetic polyneuropathy ［J］. Endocr Rev ， 2019 ， 40 （ 1 ）： 153 - 192 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Buyang Huanwutang in Treating Diabetic Peripheral Neuropathy by Inhibiting Pyroptosis Through AMPK/ULK1 Mitophagy Pathway

Inhibition of Oxidative Stress of Sciatic Nerve in Diabetic Rats by Tangbikang Granules Regulating AMPK/PGC-1α/SIRT3 Signaling Pathway

Buyang Huanwutang Treats Diabetic Peripheral Neuropathy via Mitochondrial Transport in Rats

Prevention and Treatment of Diabetic Peripheral Neuropathy by Chinese Medicine Through PI3K/Akt Signaling Pathway： A Review

Molecular Mechanism of Tangbikang Granules Against Diabetic Peripheral Neuropathy： Based on Network Pharmacology and Experimental Verification

Related Author

AN Jingwen

SONG Linchun

CHEN Die

ZHANG Wang

TIAN Jiaxin

ZHANG Tianya

BEN Ying

LIU Gang

Related Institution

College of Integrated Traditional Chinese and Western Medicine，Hebei University of Chinese Medicine，Hebei Key Laboratory of Integrated Medicine on Liver-kidney Patterns

International Joint Research Center for Diabetes Prevention and Treatment with TCM， Ministry of Science and Technology

Key Laboratory of TCM Health Sciences， Ministry of Education， Beijing University of Chinese Medicine

College of Traditional Chinese Medicine （TCM）， Beijing University of Chinese Medicine

School of Life Sciences，Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰